Adam Bergin

Adam Bergin

Auto-generated profile, based on publicly available information

Adam Bergin

School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, 152-160 Pearse St, Dublin 2, D02 R590 Dublin, Ireland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Biotechnology Advances
Verified
Journal Article
Closed access
RORoisin O'Flaherty
Roisin O'Flaherty
ABAdam Bergin
Adam Bergin
EFEvangelia Flampouri
Evangelia Flampouri
LMLetícia Martins Mota
Letícia Martins Mota
IOIsmael Obaidi
Ismael Obaidi
MBMichael Butler
Michael Butler

1 June 2021 in Analytical Biochemistry
Verified
Journal Article
Closed access
YXYongjing Xie
Yongjing Xie
LMLetícia Martins Mota
Letícia Martins Mota
ABAdam Bergin
Adam Bergin
RORoisin O'Flaherty
Roisin O'Flaherty
AJAled Jones
Aled Jones
MBMichael Butler
Michael Butler

14 December 2023 in Molecules
Verified
Journal Article
Open access
PDF file
ABAndrew Jam3s Byrne
Andrew Jam3s Byrne
SBSandra A. Bright
Sandra A. Bright
JKJames Mc Keown
James Mc Keown
ABAdam Bergin
Adam Bergin
BTBrendan Twamley
Brendan Twamley
Mary Jane MeeganMary Jane Meegan
Mary Jane Meegan
Chronic lymphocytic leukaemia (CLL) is a malignancy of the immune B lymphocyte cells and is the most common leukaemia diagnosed in developed countries. In this paper, we report the synthesis and antiproliferative effects of a series of (E)-9-(2-nitrovinyl)anthracenes and related nitrostyrene compounds in CLL cell lines and also in Burkitt’s lymphoma (BL) cell lines, a rare form of non-Hodgkin’s immune B-cell lymphoma. The nitrostyrene scaffold was identified as a lead structure for the development of effective compounds targeting BL and CLL. The series of structurally diverse nitrostyrenes was synthesised via Henry–Knoevenagel condensation reactions. Single-crystal X-ray analysis confirmed the structure of (E)-9-chloro-10-(2-nitrobut-1-en-1-yl)anthracene (19f) and the related 4-(anthracen-9-yl)-1H-1,2,3-triazole (30a). The (E)-9-(2-nitrovinyl)anthracenes 19a, 19g and 19i–19m were found to elicit potent antiproliferative effects in both BL cell lines EBV−MUTU-1 (chemosensitive) and EBV+ DG-75 (chemoresistant) with >90% inhibition at 10 μM. Selected (E)-9-(2-nitrovinyl)anthracenes demonstrated potent antiproliferative activity in CLL cell lines, with IC50 values of 0.17 μM (HG-3) and 1.3 μM (PGA-1) for compound 19g. The pro-apoptotic effects of the most potent compounds 19a, 19g, 19i, 19l and 19m were demonstrated in both CLL cell lines HG-3 and PGA-1. The (E)-nitrostyrene and (E)-9-(2-nitrovinyl)anthracene series of compounds offer potential for further development as novel chemotherapeutics for CLL.